All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III study
Keyword(s):
Keyword(s):
Keyword(s):
2015 ◽
Vol 51
(4)
◽
pp. 390-403
◽
Keyword(s):
Keyword(s):
2016 ◽
Vol 83
(3)
◽
pp. 527-539
◽
Keyword(s):
2016 ◽
Vol 49
(11)
◽
Keyword(s):
2010 ◽
Vol 82
(10)
◽
pp. 1647-1654
◽
Keyword(s):